Amicus Therapeutics Inc. (FOLD) provided updates and detailed the statistical analysis plan for its second Phase 3 study of the oral small molecule pharmacological chaperone migalastat HCl monotherapy for Fabry patients with amenable mutations Monday morning.
Amicus Therapeutics has spiked sharply to the upside in the last 15 minutes on increased volume and is currently higher by 0.75 at $3.78. The stock has soared to a new high for the year.
by RTTNews Staff Writer
For comments and feedback: editorial@rttnews.com